Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – Here’s Why

Jade Biosciences, Inc. (NASDAQ:JBIO)’s share price gapped up before the market opened on Monday . The stock had previously closed at $16.82, but opened at $17.90. Jade Biosciences shares last traded at $18.2050, with a volume of 432,648 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on JBIO shares. Weiss Ratings lowered shares of Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Wall Street Zen downgraded shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating on shares of Jade Biosciences in a report on Monday, June 1st. Piper Sandler set a $55.00 price objective on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Finally, Zacks Research upgraded Jade Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $47.12.

Jade Biosciences Stock Performance

The firm has a market capitalization of $1.08 billion, a P/E ratio of -10.82 and a beta of 1.44. The business’s fifty day moving average price is $21.12 and its two-hundred day moving average price is $17.07.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.05). Sell-side analysts predict that Jade Biosciences, Inc. will post -2.54 earnings per share for the current year.

Institutional Investors Weigh In On Jade Biosciences

A number of large investors have recently made changes to their positions in JBIO. Legal & General Group Plc purchased a new position in Jade Biosciences in the 2nd quarter worth $29,000. Russell Investments Group Ltd. purchased a new stake in Jade Biosciences during the 2nd quarter valued at about $31,000. BNP Paribas Financial Markets acquired a new position in shares of Jade Biosciences in the second quarter valued at about $32,000. California State Teachers Retirement System raised its stake in shares of Jade Biosciences by 40.3% in the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares during the last quarter. Finally, Group One Trading LLC raised its stake in shares of Jade Biosciences by 122.9% in the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock worth $65,000 after purchasing an additional 22,527 shares during the last quarter.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.